VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 beginsPreliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD)SOUTH...
Source: pharmiweb.com